Intriguingly, lirafugratinib was also able to suppress signalling and tumour growth induced by common FGFR2 kinase domain mutations associated with acquired resistance to pan-FGFR inhibitor treatment in cholangiocarcinoma patients such as the FGFR2V564F gatekeeper mutation. Here, FGFR2 is linked to cholangiocarcinoma.